Literature DB >> 9202062

Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice.

K Tsukamoto1, P Smith, J M Glick, D J Rader.   

Abstract

Apolipoprotein E (apoE) plays a key role in lipoprotein metabolism and may have other important biological functions. In humans, there are three common, naturally occurring isoforms of apoE that are associated with differences in lipid levels and atherosclerosis. However, the direct in vivo effects of the apoE isoforms on lipoprotein metabolism and atherosclerosis are not yet fully understood. To investigate the effect of the apoE isoforms in vivo, we constructed second-generation recombinant adenoviruses encoding each of the apoE isoforms. These recombinant adenoviruses were injected intravenously into apoE-deficient mice fed a Western diet (mean baseline cholesterol level 1401 mg/dl) in order to study their effects in the absence of endogenous mouse apoE. Hepatic expression of apoE3 and apoE4 completely normalized the lipoprotein profile; 3 d after injection, mean plasma cholesterol levels were 194 and 217 mg/ dl, respectively, and this effect was maintained for at least 6 wk. Expression of apoE2 had much less effect on lipoprotein levels (mean cholesterol level 752 mg/dl 3 d after injection), despite much higher plasma levels of apoE2 compared with apoE3 and apoE4; by 6 wk after injection the cholesterol levels had returned to baseline levels in the apoE2-expressing mice. Expression of all three isoforms significantly increased HDL cholesterol levels by approximately threefold and was independent of the cholesterol-lowering effect. ApoE transgene expression was substantially prolonged compared with that achieved using a first generation adenovirus and apoE was readily detected in plasma 3 mo after virus injection. These studies demonstrate: (a) prolonged in vivo expression of human apoE isoforms in apoE deficient mice after second-generation recombinant adenovirus-mediated somatic gene transfer; and (b) significantly impaired ability of apoE2 in vivo to mediate clearance of remnant lipoproteins in apoE-deficient mice fed a Western diet compared with apoE3 and apoE4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202062      PMCID: PMC508170          DOI: 10.1172/JCI119501

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Adenovirus-mediated gene transfer as an in vivo probe of lipoprotein metabolism.

Authors:  J M Leiden
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

2.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 3.  The formation of LDL: mechanisms and regulation.

Authors:  R J Havel
Journal:  J Lipid Res       Date:  1984-12-15       Impact factor: 5.922

4.  Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E.

Authors:  R E Gregg; L A Zech; E J Schaefer; H B Brewer
Journal:  Science       Date:  1981-02-06       Impact factor: 47.728

5.  Abnormal in vivo metabolism of apolipoprotein E4 in humans.

Authors:  R E Gregg; L A Zech; E J Schaefer; D Stark; D Wilson; H B Brewer
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

Review 6.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

7.  NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.

Authors:  H B Brewer; L A Zech; R E Gregg; D Schwartz; E J Schaefer
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

Review 8.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency.

Authors:  H Mabuchi; H Itoh; M Takeda; K Kajinami; T Wakasugi; J Koizumi; R Takeda; C Asagami
Journal:  Metabolism       Date:  1989-02       Impact factor: 8.694

10.  Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.

Authors:  C Ehnholm; R W Mahley; D A Chappell; K H Weisgraber; E Ludwig; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

View more
  17 in total

Review 1.  Regression of atherosclerosis: insights from animal and clinical studies.

Authors:  Jonathan E Feig
Journal:  Ann Glob Health       Date:  2013-12-25       Impact factor: 2.462

2.  Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.

Authors:  Sadik H Kassim; James M Wilson; Daniel J Rader
Journal:  Clin Lipidol       Date:  2010-06

3.  Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice.

Authors:  Min Liu; David G Kuhel; Ling Shen; David Y Hui; Stephen C Woods
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-29       Impact factor: 3.619

4.  Impact of dietary fat type within the context of altered cholesterol homeostasis on cholesterol and lipoprotein metabolism in the F1B hamster.

Authors:  Jaime L Lecker; Nirupa R Matthan; Jeffrey T Billheimer; Daniel J Rader; Alice H Lichtenstein
Journal:  Metabolism       Date:  2010-03-02       Impact factor: 8.694

Review 5.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

6.  Limited Macrophage Positional Dynamics in Progressing or Regressing Murine Atherosclerotic Plaques-Brief Report.

Authors:  Jesse W Williams; Catherine Martel; Stephane Potteaux; Ekaterina Esaulova; Molly A Ingersoll; Andrew Elvington; Brian T Saunders; Li-Hao Huang; Andreas J Habenicht; Bernd H Zinselmeyer; Gwendalyn J Randolph
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

7.  Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice.

Authors:  Catherine Martel; Wenjun Li; Brian Fulp; Andrew M Platt; Emmanuel L Gautier; Marit Westerterp; Robert Bittman; Alan R Tall; Shu-Hsia Chen; Michael J Thomas; Daniel Kreisel; Melody A Swartz; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

8.  Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

Authors:  M M Véniant; C H Zlot; R L Walzem; V Pierotti; R Driscoll; D Dichek; J Herz; S G Young
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia.

Authors:  Sadik H Kassim; Hui Li; Peter Bell; Suryanarayan Somanathan; William Lagor; Frank Jacobs; Jeffrey Billheimer; James M Wilson; Daniel J Rader
Journal:  Hum Gene Ther       Date:  2012-11-14       Impact factor: 5.695

10.  A practical approach to using mice in atherosclerosis research.

Authors:  Stewart C Whitman
Journal:  Clin Biochem Rev       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.